Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumuors

Annals of Oncology

Volumn 11, Issue 3, 2000, Pages 295-300

  Imam, H ^a   Eriksson, B ^a   Oberg K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD44 isoforms; Endocrine pancreatic tumour; Immunohistochemistry; Tumour proliferation

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; DISEASE ASSOCIATION; GASTRINOMA; GLUCAGONOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; MALIGNANT NEOPLASTIC DISEASE; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROGNOSIS;

ADENOMA, ISLET CELL; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033996006     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008333812548     Document Type: Article

References (36)

1. Gunthert U. CD44: A multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993; 184: 47-63.
2. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993; 54: 271-335.
3. Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: Key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol 1994; 6: 726-33.
4. Sherman L, Sleeman J, Dall P et al. The CD44 proteins in embryonic development and in cancer. Curr Top Microbiol Immunol 1996; 213: 249-69.
5. Screaton GR, Bell MV, Jackson DG et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Nail Acad Sci USA 1992; 89: 12160-4.
6. Gunthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
7. Hofmann M, Rudy W, Zoller M et al. CD44 splice variants confer metastatic behavior in rats: Homologous sequences are expressed in human tumor cell lines. Cancer Res 1991; 51: 5292-7.
8. East JA, Hart IR. CD44 and its role in tumour progression and metastasis. Eur J Cancer 1993; 29A: 1921-2.
9. Gunthert U, Hofmann M, Rudy W et al. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 1995; 24: 19-42.
10. Eriksson B, Arnberg H, Lindgren PG et al. Neuroendocrine pancreatic tumours: Clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990; 228: 103-13.
11. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996; 7: 453-63.
12. Gotoda T, Matsumura Y, Kondo H et al. Expression of CD44 variants and its association with survival in pancreatic cancer. Jpn J Cancer Res 1998; 89: 1033-40.
13. Hirata T, Fukuse T, Naiki H et al. Expression of CD44 variant exon 6 in stage I non-small-cell lung carcinoma as a prognostic factor. Cancer Res 1998; 58: 1108-10.
14. Neumayer R, Rosen HR, Reiner A et al. CD44 expression in benign and malignant colorectal polyps. Dis Colon Rectum 1999; 42: 50-5.
15. Regauer S, Ott A, Berghold A, Beham A. CD44 expression in sinonasal melanomas: Is loss of isoform expression associated with advanced tumour stage? J Pathol 1999; 187: 184-90.
16. Inagaki H, Banno S, Wakita A et al. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Mod Pathol 1999; 12: 546-52.
17. Dall P, Heider KH, Sinn HP et al. Comparison of immunohistochemistry and RT PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995; 60: 471-7.
18. Chaudhry A, Gobl A, Eriksson B et al. Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Cancer Res 1994; 54: 981-6.
19. Funa K, Papanicolaou V, Juhlin C et al. Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 1990; 50: 748-53.
20. Grimelius L, Wilander E. Silver stains in the study of endocrine cells of the gut and pancreas. Invest Cell Pathol 1980; 3: 3-12.
21. Wilander E, Lundqvist M, Oberg K. Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects. Prog Histochem Cytochem 1989; 19: 1-88.
22. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992; 340: 1053-8.
23. Iida N, Bourguignon LY. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995; 162: 127-33.
24. Kaufmann M, Heider KH, Sinn HP et al. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-9.
25. Martegani MP, Del Prete F, Gasbarri A et al. Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant exon products. Am J Pathol 1999; 154: 291-300.
26. Stauder R, Eisterer W, Thaler J, Gunthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 1995; 85: 2885-99.
27. Hong RL, Lee WJ, Shun CT et al. Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology 1995; 52: 334-9.
28. Soukka T, Salmi M, Joensuu H et al. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 1997; 57: 2281-9.
29. Guriec N, Gairard B, Marcellin L et al. CD44 isoforms with exon v6 and metastasis of primary NOMO breast carcinomas. Breast Cancer Res Treat 1997; 44: 261-8.
30. Granberg D, Wilander E, Oberg K, Skogseid B. Decreased survival in patients with CD44-negative typical bronchial carcinoid tumors. Int J Cancer 1999; 84: 484-8.
31. Hofmann M, Rudy W, Günthert U et al. A link between ras and metastatic behavior of tumor cells: Ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 1993; 53: 1516-21.
32. Herrlich P, Zoller M, Pals ST, Ponta H. CD44 splice variants: Metastases meet lymphocytes. Immunol Today 1993; 14: 395-9.
33. Chaudhry A, Oberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 1992; 13: 27-35.
34. Pelosi G, Bresaola E, Bogina G et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27: 1124-34.
35. La Rosa S, Sessa F, Capella C et al. Prognostic criteria in non-functioning pancreatic endocrine tumours. Virchows Arch 1996; 429: 323-33.
36. Gentil Perret A, Mosnier JF, Buono JP et al. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol 1998; 109: 286-93.